46,500 Shares in Mesoblast Limited $MESO Purchased by Rialto Wealth Management LLC

Rialto Wealth Management LLC acquired a new position in shares of Mesoblast Limited (NASDAQ:MESO) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 46,500 shares of the company’s stock, valued at approximately $839,000.

A number of other large investors also recently added to or reduced their stakes in the business. Legal & General Group Plc acquired a new stake in shares of Mesoblast during the 3rd quarter worth approximately $10,501,000. Goldman Sachs Group Inc. acquired a new position in Mesoblast in the first quarter valued at approximately $3,209,000. Bank of America Corp DE boosted its stake in Mesoblast by 791.7% in the third quarter. Bank of America Corp DE now owns 111,459 shares of the company’s stock valued at $1,796,000 after acquiring an additional 98,960 shares during the last quarter. Brooklyn Investment Group bought a new position in Mesoblast in the third quarter valued at approximately $655,000. Finally, Squarepoint Ops LLC grew its holdings in Mesoblast by 116.8% during the 3rd quarter. Squarepoint Ops LLC now owns 31,656 shares of the company’s stock worth $510,000 after acquiring an additional 17,053 shares during the period. 1.43% of the stock is currently owned by institutional investors and hedge funds.

Mesoblast Stock Down 2.4%

NASDAQ:MESO opened at $14.02 on Tuesday. Mesoblast Limited has a 1 year low of $9.61 and a 1 year high of $21.50. The stock has a 50-day moving average price of $16.54 and a two-hundred day moving average price of $16.90. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -15.93 and a beta of 2.17. The company has a current ratio of 1.58, a quick ratio of 1.41 and a debt-to-equity ratio of 0.10.

Mesoblast (NASDAQ:MESO) last released its quarterly earnings results on Thursday, January 29th. The company reported ($0.16) EPS for the quarter. The firm had revenue of $25.67 million during the quarter. As a group, equities analysts expect that Mesoblast Limited will post -0.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mesoblast in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Mesoblast has a consensus rating of “Moderate Buy”.

Mesoblast Company Profile

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.